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Cognitive dysfunctionThe serotonergic system plays an important role in cognitive functions via various 5-HT receptors. Vortioxetine
(Lu AA21004) in development as a novel multimodal antidepressant is a 5-HT3, 5-HT7 and 5-HT1D receptor an-
tagonist, a 5-HT1B receptor partial agonist, a 5-HT1A receptor agonist and a 5-HT transporter (5-HTT) inhibitor in
vitro. Preclinical studies suggest that 5-HT3 and 5-HT7 receptor antagonism as well as 5-HT1A receptor agonism
mayhave a positive impact on cognitive functions includingmemory. Thus vortioxetinemay potentially enhance
memory.We investigated preclinical effects of vortioxetine (1–10 mg/kg administered subcutaneously [s.c.]) on
memory in behavioral tests, and on cortical neurotransmitter levels considered important in rat memory func-
tion. Contextual fear conditioning and novel object recognition tests were applied to assess memory in rats. Mi-
crodialysis studies were conducted to measure extracellular neurotransmitter levels in the rat medial prefrontal
cortex. Vortioxetine administered 1 h before or immediately after acquisition of contextual fear conditioning led
to an increase in freezing time during the retention test. Thismnemonic effect was not related to changes in pain
sensitivity as measured in the hotplate test. Rats treated with vortioxetine 1 h before training spent more time
exploring the novel object in the novel object recognition test. In microdialysis studies of the rat medial prefron-
tal cortex, vortioxetine increased extracellular levels of acetylcholine and histamine. In conclusion, vortioxetine
enhanced contextual and episodicmemory in rat behavioralmodels. Further demonstration of its potential effect
on memory functions in clinical settings is warranted.
© 2013 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
The most frequently used pharmacological treatments for major
depressive disorder (MDD) include the selective serotonin reuptake
inhibitors (SSRIs) and the serotonin and norepinephrine (NE) reuptake
inhibitors (SNRIs)whereas the older tricyclic antidepressants andmono-
amine oxidase inhibitors are less used because of their adverse effects.
While the SSRIs and SNRIs may generate only a limited antidepressantorter; ACh, Acetylcholine; HA,
c serotonin reuptake inhibitor;
rder; PCP, Phencyclidine; s.c.,
inhibitor; US, Unconditioned
ors was performed as full time
e study.
45 36 43 82 32.
en Inc., One Amgen Center Dr.,
NC-ND license.response (Rush et al., 2006), improved responses have been seen with
different or combined therapies involving additional mechanisms, such
as the allosteric serotonin reuptake inhibitor (ASRI) escitalopram
(Cipriani et al., 2009; Montgomery et al., 2011; Zhong et al., 2012), as
well as combination medications, such as venlafaxine plus bupropion
(Fatemi et al., 1999), SSRIs plus pindolol (Artigas et al., 2006), or SSRIs
augmented with atypical antipsychotics such as aripiprazole (Nelson
and Papakostas, 2009).
Signiﬁcant unmet needs still exist in the treatment of depression, in-
cluding deﬁcits inmemory and executive functions, symptoms that may
persist beyond clinical recovery (Hasselbalch et al., 2011). Ameliorating
deﬁcits in cognitive functionsmay also be an important part of treatment
of depression and other CNS disorders (Clark et al., 2009;Marazziti et al.,
2010). Studies combining neuropsychological testing, psychiatric exam-
ination, and neuroimaging showed that patients with depressive disor-
ders suffer from widespread cognitive dysfunction (Ravnkilde et al.,
2002; Bhardwaj et al., 2010). One of the current cognitive theories of de-
pression suggests that depression may present as an increased elabora-
tion of negative information, difﬁculties in disengaging from negative
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information (Gotlib and Joormann, 2010). Efforts directed at reducing
cognitive dysfunctions in depression may have the potential to reduce
disability (Naismith et al., 2007), and interventions targeting cognitive
dysfunctions may be an important strategy for the treatment of
depression.
Some potential pharmacological interventions to address cognitive
dysfunctions in mental disorders have been reported (for a recent re-
view, see (Wallace et al., 2011)). A large body of evidence indicates
that the 5-HT system plays an important role in cognitive functions,
such as learning and memory, as demonstrated through the activation
or blockade of 5-HT receptor subtypes, such as the 5-HT1A, 5-HT1B,
5-HT2, 5-HT3, 5-HT4, 5-HT6, and 5-HT7 receptors (Buhot, 1997;
Meneses and Hong, 1997; Roman and Marchetti, 1998; Buhot et al.,
2000; Meneses, 2007; King et al., 2008). Among them, the 5-HT3 and
5-HT7 receptors are particularly interesting. Compelling preclinical
data from studies in rodents suggest beneﬁcial effects on memory of
5-HT3 receptor antagonists such as ondansetron (Fontana et al., 1995;
Akhondzadeh et al., 2009), itasetron (Pitsikas and Borsini, 1996),
WAY-100579 (Hodges et al., 1996), and the 5-HT7 receptor antagonist
SB-269970 (Meneses, 2004; McLean et al., 2009; Horiguchi et al.,
2011; Horisawa et al., 2011). However, none of these compounds has
yet reached clinical practice for the treatment of cognitive deﬁcits.
Vortioxetine a novel multimodal antidepressant (Adell, 2010;
Alvarez et al., 2012) currently under development for the treatment of
MDD, is a 5-HT3A receptor antagonist (Ki=3.7 nM), 5-HT7 receptor
antagonist (Ki=19 nM), 5-HT1D receptor antagonist (Ki=54 nM),
5-HT1B receptor partial agonist (Ki=33 nM), 5-HT1A receptor agonist
(Ki=15 nM) and 5-HTT inhibitor (Ki=1.6 nM) asmeasured in recom-
binant cell lines expressing these human 5-HT receptors and 5-HT
transporter (Bang-Andersen et al., 2011; Westrich et al., 2012) (see
Table 1). Preclinical and clinical studies have demonstrated the antide-
pressant properties of vortioxetine (Adell, 2010; Mørk et al., 2012;
Alvarez et al., 2012; Katona et al., 2012), and a recent clinical study in el-
derly depressed patients showed superiority to placebo in cognitive
tests of speed processing, verbal learning and memory (Katona et al.,
2012). Based on these clinical observations and the pharmacological
proﬁle of vortioxetine, we investigated its potential and related mecha-
nisms to enhance memory in behavioral and microdialysis studies in
rats.
Twomemory testswere used, i.e., the rat contextual fear conditioning
and novel object recognition tests. In the classical fear-conditioning par-
adigm, animals learn to associate a neutral environment (context, as a
conditioned stimulus, CS) with an aversive experience, i.e., an electrical
foot-shock as an unconditioned stimulus (US). Upon re-exposure to the
CS, animals will demonstrate freezing behavior as a sign of fear-related
memory (Fanselow, 1980). In order to rule out possible analgesic effects
of vortioxetine in affecting the behavioral results in the memory tests,Table 1
The in vitro pharmacological proﬁle and in vivo target occupancies of vortioxetine. The in v
occupancies in the rat and human are summarized based on previous reports as referenced
Target Type of activity Binding Ki or potency IC50 (nM)
Human Rat
5-HT3A Antagonist 3.7a 1.1b
5-HT7 Antagonist 19a 200d
5-HT1D Antagonist 54e 3.7e
5-HT1B Partial agonist 33a 16d
5-HT1A Agonist 15a 230a
5-HTT Inhibitor 5.4 (IC50 on uptake)a 5.3 (IC50 on upta
ND, not determined.
a Bang-Andersen et al. (2011).
b Sanchez et al. (2012).
c Pehrson et al. (2013).
d Mørk et al. (2012).
e Westrich et al. (2012).
f Areberg et al. (2012).the pain threshold was assessed by a hotplate method, as previously de-
scribed (Montezinho et al., 2010). The novel object recognition task is a
memory test that takes advantage of a rodent's innate drive to spontane-
ously explore novelty in its environment, and involves several brain
structures, including the hippocampus and the medial prefrontal cortex
(Ennaceur and Delacour, 1988; Antunes and Biala, 2012).
The present study also examined extracellular levels of acetylcholine
(ACh) and histamine (HA), two neurotransmitters involved in regula-
tion of memory function, in freely moving rats following vortioxetine
administration. We have previously shown that vortioxetine increases
the level of extracellular 5-HT, as well as the levels of dopamine and
norepinephrine in the rat prefrontal cortex and hippocampus
(Bang-Andersen et al., 2011; Mørk et al., 2012). The receptor mecha-
nisms mediating the effects of vortioxetine may also modulate the
properties of cholinergic and histaminergic neurons via their role as
presynaptic heteroreceptors or postsynaptic receptors, or indirectly
through interneurons.
2. Materials and methods
2.1. Animals
Studies were carried out in male Sprague–Dawley rats from Charles
River (250–300 g, 7–8 weeks). All animals were housed two per cage
under a 12 h light/dark cycle in a temperature- (21±2 °C) and
humidity- (60±10%) controlled environment. Food and water were
available ad libitum. Rats were used 1 week after arrival. The fear condi-
tioning and ACh microdialysis experiments were carried out at H
Lundbeck A/S, Denmark and ethical permissions were granted by the an-
imal welfare committee appointed by the Danish Ministry of Justice. All
animal procedures for these studies were carried out in compliance
with the EC directive 86/609/EEC and Danish law regulating experiments
on animals. The HA microdialysis study was carried out at Brainsonline
(The Netherlands) as described previously (Flik et al., 2011). The novel
object recognition and hotplate studies were conducted at Lundbeck Re-
search, USA and were approved by the Institutional Animal Care and Use
Committee (IACUC) of Lundbeck Research USA, Inc.
2.2. Drugs
In the fear conditioning, hotplate, and microdialysis studies,
vortioxetine (1-[2-(2,4-dimethylphenyl-sulfanyl)-phenyl]-piperazine)
was dissolved in 10% aqueous hydroxypropyl-ß-cyclodextrin and
injected subcutaneously (s.c.), in a volume of 2.5 ml/kg. In novel object
recognition studies, vortioxetine was dissolved in 20% aqueous
hydroxypropyl-ß-cyclodextrin and administered s.c. in a volume of
2.0 ml/kg, 60 min prior to training. All doses used are expressed asitro activities of vortioxetine at different 5-HT targets and their corresponding in vivo
.
In vivo occupancy
Human Rat
ND 100% at 1 mg/kg; ED50 0.004 mg/kgc
ND ND
ND ND
ND ~80% at 10 mg/kg; ED50 3.2 mg/kgd
ND 28%, 35%, 44% at 5, 10, 20 mg/kg, respectivelyc
ke)a ~50% at 5 mgf >80% at 10 mg/kg; ED50 0.4 mg/kgd
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in all experiments.2.3. Contextual fear conditioning
2.3.1. Apparatus
Training and testing were conducted in a soundproof chamber
(30×20×40 cm) kept in an isolated room and connected to a venti-
lation system. Illumination was provided by an incandescent white
light (60 W). The ﬂoor of the chamber consisted of a metal grid at-
tached to an electric shock generator. Prior to training and testing,
the chamber was cleaned with 70% ethanol. A video camera was
used for behavioral observations and recording of the training session
for off-line analysis. The white light and current were controlled by
FCON win software (Ellegaard Systems, Denmark). Animal behavior
was recorded by EthoVision3.0 (Noldus, Netherlands).2.3.2. Behavioral measurement
Freezing was used to assess conditioned fear as described previously
(Fendt and Fanselow, 1999). During acquisition, animalswere allowed to
freely explore the novel environment for a 1 min habituation period,
which terminated with a US consisting of one inescapable foot-shock
through the electriﬁable grid ﬂoor. The foot-shock had a 2-s duration
and an intensity of 0.75 mA when drugs were dosed before acquisition
or during memory consolidation or 1.5 mA when drugs were dosed
before the retention test in order to increase the freezing behavior of
the animals. Animals remained in the conditioning chamber for
another 60 s after the US. Freezing behavior was scored during the ﬁrst
58 s (pre-US acquisition) by an experimenter blinded to treatment in
order to establish baseline-freezing responses to the context. At the
end of the acquisition, animals were removed and returned to their
home cages. To test fear conditioning associated with context, each rat
was placed back in the chamber as a contextual conditioned stimulus
(CS) for 2 minwith no foot-shocks applied, 24 h after acquisition. Freez-
ing behavior was manually scored during the whole test period and
presented as percent of the total test period, againwith the experimenter
blinded to treatment group.
To assess the effects of vortioxetine on acquisition of fear condition-
ing, vehicle or vortioxetine (1, 5 or 10 mg/kg)was administered 60 min
before acquisition (CS–US). The animals were tested (CS) 24 h later. To
test the effect of vortioxetine on the consolidation of contextual fear
memory, vehicle or vortioxetine (5 or 10 mg/kg) were given immedi-
ately after acquisition (CS–US). The animals were tested (CS) 24 h
later. To investigate the effects of vortioxetine on retention (memory re-
call) or expression of fear conditioning, vehicle or vortioxetine (5 or
10 mg/kg) was given to the animals 24 h after acquisition (CS–US),
which was 60 min before the testing of contextual conditioning (CS).
These different time points for vortioxetine administrationwith respect
to fear acquisition and contextual freezing test are shown in Fig. 1.Fig. 1. Diagram showing the different time points for vortioxetine administration with re
60 min before acquisition, immediately after acquisition, or 24 h after acquisition but 60 m
of fear conditioning and the consolidation or retention of contextual memory, respectively.2.4. Novel object recognition
2.4.1. Apparatus
The novel object recognition taskwas adapted fromprevious studies
(Ennaceur and Delacour, 1988). The experimental apparatus consisted
of a rectangular opaque plastic chamber (61 cm×42 cm×37 cm)
with bedding on the ﬂoor. The objects were either a goblet (11 cm in
height, 6.5 cm in diameter) or a conical candlestick holder (11 cm in
height, 6 cm in diameter) both made of green, nontransparent glass.
Multiple copies of each object were used for training and testing and
object pairs were randomly assigned between and within conditions.
During each day of experimentation, as described below, the rats were
transported in their home cages from the vivarium to a dimly lit
(5–6 lx) testing room and acclimated to the room for approximately
45 min before being tested. In addition, after testing each rat, the ob-
jects and chamberwallswere thoroughly cleanedwith a Clidox solution
to remove any residual olfactory cues.
2.4.2. Behavioral measurement
On day 1, each rat was individually placed in the empty training–
testing chamber for 5 min of free exploration. Before being transported
back to the vivarium, the ratwas returned to its home cage and remained
in the testing room until all rats were habituated. On day 2, training for
each rat began in the empty chamber, positioned with nose centered to
a long wall. After 1 min of re-habituation, the rat was removed from
the chamber and placed in a holding cage for approximately 10 s while
two identical training objects were positioned 8 cm from the center of
the shortwalls. The ratwas returned to the chamber for 15 min of explo-
ration. Movements were observed via a camera located above the cham-
ber and recorded. Before being transported back to the vivarium, the rat
was returned to his home cage and remained in the testing roomuntil all
rats were trained.
Testing of each rat began in the empty chamber 24 h later. The test
procedure was similar to the training procedure, except that one
object was identical to the training object, while the other was
novel. The position of the novel object was randomly assigned (left
or right) and balanced for each rat and treatment group. The rat
was allowed to actively explore for 15 min or until 60 s of total object
exploration was accumulated. Object exploration was only scored if
the rat's nose was within 1 cm of the object and its vibrissae were
moving. Failure to explore both objects resulted in exclusion of the
data of this animal from the study.
Rats were randomly assigned to one of 5 treatment groups (vehicle
or vortioxetine, 2.5, 5 or 10 mg/kg or the positive control donepezil
1.0 mg/kg) and dosed 60 min prior to novel object recognition training.
The acetylcholinesterase inhibitor donepezil was used since it has been
often used as a positive control compound in different memory tests
done in animals in our previous studies. During the test, exploration
times of the familiar and novel objects were recorded and the mean
time spent exploring each object was calculated. In addition, percent
novel exploration, expressed as the percentage of time spent exploringspect to fear acquisition and contextual freezing test. Vortioxetine was administered
in before the contextual freezing test, in order to assess possible effects on acquisition
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jects [100∗(novel time)/(novel time+familiar time)] was analyzed.
2.5. Hotplate test
The hotplate apparatus (IITC Life Science, USA) was equipped with
a built-in heater and a square Plexiglas enclosure to contain the ani-
mals. Vortioxetine (2.5, 5 or 10 mg/kg) or vehicle was administered
s.c., 30 min prior to testing. The animals were placed on the hotplate
at 50 °C. The latency to a discomfort reaction was scored manually
with a stopwatch by an experimenter blind to the drug condition of
the subjects. The response endpoint was deﬁned as either withdrawal
or licking of the forepaw or hind paw. Test time was limited to 120 s
to minimize the discomfort of the animal.
2.6. Microdialysis
The effect of vortioxetine (2.5, 5 or 10 mg/kg) on extracellular
levels of ACh and HA in the medial prefrontal cortex was determined
by microdialysis in freely moving rats. The surgery and microdialysis
procedures were performed as previously reported (Flik et al., 2011;
Mørk et al., 2012). When studying effects on extracellular levels of
ACh, the microdialysis perfusion solution contained 0.5 μM neostig-
mine (Sigma-Aldrich, USA) to increase the sensitivity of the method
and to increase the basal ACh levels to detectable levels. The mea-
sured content of neurotransmitters in the dialysates was not been
corrected for in vitro recovery of the microdialysis probes.
2.6.1. Analysis of acetylcholine in dialysate
Concentrations of ACh in the dialysates were analyzed bymeans of
HPLC with electrochemical detection using a mobile phase consisting
of 100 mM disodium hydrogen phosphate, 2.0 mM octane sulfonic
acid, 0.5 mM tetramethyl-ammonium chloride and 0.005% MB (Envi-
ronmental Sciences Associates, ESA), pH 8.0. A pre-column enzyme
reactor (ESA), containing immobilized choline oxidase, removed cho-
line from the injected sample (10 μl) prior to separation of ACh on the
analytical column (ESA ACH-250); ﬂow rate 0.35 ml/min, tempera-
ture 35 °C. After the analytical column the sample passed through a
post-column solid phase reactor (ESA) containing immobilized acetyl
cholinesterase and choline oxidase. The latter reactor converted ACh
to choline and subsequently choline to betaine and H2O2. The latter
was detected electrochemically using a platinum electrode (Analyti-
cal cell, ESA, model 5040).
2.6.2. Analysis of histamine in dialysate
Concentrations of HA were determined by HPLC combined with
tandem mass spectrometry (MS/MS) detection using an internal
standard. Samples were mixed with the internal standard solution,
and were derivatized with SymDAQ (symmetrical dialdehyde quater-
nary ions). After a reaction time of 2 min 50 μl of the mixture was
injected into the LC system by an automated sample injector
(SIL-10 AD vp, Shimadzu, Japan). Chromatographic separation was
performed on a reverse phase Hypersil 50×2.1 mm (1.9 μm particle
size) column held at a temperature of 35 °C. Components were sepa-
rated using a linear gradient of acetonitrile/0.1% formic acid in 0.1%
formic acid (ﬂow rate 0.2 ml/min). MS analyses were performed
using an API 4000 MS/MS system consisting of an API 4000 MS/MS
detector and a Turbo Ion Spray interface (both from Applied
Biosystems, The Netherlands). Data were calibrated and quantiﬁed
using the Analyst™ data system (Applied Biosystems, version 1.4.2).
The mean value of 3 to 4 consecutive dialysis samples immediately
preceding compound administration served as the basal level for
each experiment and data were converted to percentage of basal
(mean basal pre-injection values normalized to 100%).2.7. Data and statistical analyses
Data were analyzed with GraphPad Prism 4 (GraphPad, San Diego,
CA). In contextual fear conditioning and hot-plate tests, statistical anal-
yses were done using one-way Analysis of Variance (ANOVA), followed
by Dunnett's post hoc test comparing all dose groups versus the control
group. In the novel object recognition test (for raw seconds of novel ver-
sus familiar object exploration) and microdialysis studies, statistical
analyses were conducted using two-way repeated measures ANOVA,
followed by Bonferroni's or Student–Newman–Keuls post-hoc test. For
the percent novel exploration analysis in the novel object recognition
test, one-way ANOVA was used followed by Dunnett's Multiple Com-
parisons Test.
3. Results
3.1. Contextual fear conditioning
All groups displayed increased freezing rates compared to baseline
(before acquisition) when exposed to the conditioning chamber 24 h
after acquisition (Fig. 2a), indicating successful retention of the aversive
memory towards the CS. Animals treated with vortioxetine 60 min be-
fore acquisition signiﬁcantly increased freezing [F(3, 34)=4.3, Pb0.05,
one-way ANOVA], suggesting enhanced contextual memory formation
during acquisition and/or consolidation. Post hoc tests indicated a sig-
niﬁcant increase in freezing at 10 mg/kg compared to the vehicle
control group (Pb0.01). This effect appeared to be dose dependent in
that 1 mg/kg did not have any effect, whereas 5 mg/kg produced a
non-signiﬁcant increase. Administration of vortioxetine 60 min before
acquisition did not affect freezing at baseline, i.e., prior to the exposure
to the foot shock during acquisition (Fig. 2a). This indicates that the
drug had no nonspeciﬁc effect on freezing behavior.
To isolate the effect of vortioxetine on the consolidation phase, we
administered the drug immediately after acquisition. Here, interesting-
ly, vortioxetine treatment also caused increased freezing rates during
retention [F(2, 43)=3.5, Pb0.05, one-way ANOVA], an effect that
reached statistical signiﬁcance by post hoc tests at the 5 mg/kg dose
compared to vehicle (Pb0.05) (Fig. 2b). At 10 mg/kg dose, there was a
trend towards an increase that did not reach statistical signiﬁcance.
Finally, when vortioxetine was administered 60 min before the re-
tention test to assess its possible effect on the expression of fear con-
ditioning, there was no signiﬁcant effect on freezing [F(2, 34)=1.4,
P=0.25, one-way ANOVA] (Fig. 2c).
3.2. Novel object recognition
To test vortioxetine in an episodic-like memory test that does not
rely on aversive memory formation, we applied the novel object recog-
nition task. We used a 24-h interval between acquisition and retention
trials,which has been shown to be sufﬁcient for the natural forgetting of
familiar objects (Ennaceur and Delacour, 1988). Indeed, vehicle-treated
animals explored the objects to a similar degree (Fig. 3a), and the per-
formance of both groups was that expected by chance (Fig. 3b). Rats
treated with 2.5 or 5 mg/kg vortioxetine prior to acquisition showed
average exploration times of 29 and 33 s for the novel object, respec-
tively (Fig. 3a). These correspond to 51% and 52% of the total exploration
time (Fig. 3b), which were similar to the times for the vehicle group.
Two-way repeatedmeasures ANOVA indicated that there were a signif-
icant discrimination between novel versus familiar objects [F(1, 35)=
14.9, Pb0.001], and a signiﬁcant treatment×object interaction [F(4,
35)=3.5, Pb0.05], though the dose effect was not signiﬁcant [F(4,
35)=1.1, NS] (Fig. 3a). Post hoc analyses showed that pretreatment
with vortioxetine at 10 mg/kg signiﬁcantly enhanced novel versus fa-
miliar object recognition time to 49 s as compared to the 28 s for vehi-
cle (Pb0.01, Fig. 3a). In addition, no signiﬁcant difference was observed
between 5 and 10 mg/kg doses of vortioxetine on time spent with the
Fig. 2. The effects of vortioxetine on the time spent freezing during the retention test in a
contextual fearing conditioningmodel. Freezing behavior was used to assess contextually
conditioned fear in male Sprague–Dawley rats as described in Materials and methods.
During acquisition, animals were placed in a novel environmental chamber for 1 min,
which co-terminated with an unconditioned stimulus (US) consisting of one inescapable
foot-shock. 24 h after acquisition, the rat was placed back in the chamber for 2 min with
no foot-shock applied, during which freezing behavior was scored. The average percent-
age of time spent freezing for each treatment group during the 58-s habituation period
prior to the foot shock US (pre-shock acquisition) (white bars) and when measured
24 h after acquisition (retention test) (solid bars) are shown. Vortioxetine was adminis-
tered 60 min before acquisition (a), immediately after the acquisition (b), or 60 min
prior to the retention test (c). Results are expressed as mean±SEM (n=number of ani-
mals per group). Data were analyzed by one way ANOVA, followed by Dunnett's post
hoc test. *Pb0.05, **Pb0.01 versus vehicle control.
Fig. 3. Vortioxetine increased the time rats spent investigating the novel object in the rat
24-h novel object recognition test. The habituation, training and testing procedures for
novel object recognition test are described in Materials and methods. After a 24-h delay
post training with 2 identical familiar objects, the rats were allowed to actively explore
a familiar object together with a novel object for 15 min or until 60 s of total object explo-
ration was accumulated. Eight rats were randomly assigned to one of 5 treatment groups
(vehicle or vortioxetine, 2.5, 5 or 10 mg/kg or positive control donepezil 1.0 mg/kg) and
dosed 60 min prior to novel object recognition training. During the test, exploration
times for both the familiar and novel objects were recorded and mean time spent explor-
ing each object was derived (a). In addition, the percent novel exploration, expressed as
the percentage of time spent exploring the novel object in relation to the total time
spent exploring both objects, was calculated (b). Results are expressed as mean±SEM
(n=8 animals per group). Data were analyzed using a two-way repeated measures
ANOVA, followed by Bonferroni's test (for raw seconds of novel versus familiar explora-
tion, interaction between dose and object), and a one-way ANOVA, followed by Dunnett's
multiple comparisons test versus vehicle control (percent novel exploration). *Pb0.05,
**Pb0.01, n=8 per group.
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were compared a signiﬁcant treatment effect [F(4, 35)=3.7, Pb0.05,
onewayANOVA]was observed. The numerical increase for vortioxetine
compared to vehicle approached but did not reach statistical signiﬁ-
cance (66%±4% of total exploration time) (Fig. 3b). As a positivecontrol, donepezil (1 mg/kg) also signiﬁcantly (Pb0.01) increased rec-
ognition memory, with a mean novel object exploration time of 38 s
(Fig. 3a) or 70% of total exploration time (Fig. 3b) as compared to vehi-
cle (28 s, or 50% of total exploration time).
During novel object recognition training, rats were allowed to
explore two identical objects. During 5, 10 or 15 min periods, the accu-
mulative exploration times were 33–36 s, 55–68 s, and 73–93 s, respec-
tively (data not shown). There was no signiﬁcant difference between
treatment groups [F(4, 10)=0.1, NS].3.3. Hotplate test
The hotplate test was conducted to rule out the possibility that the
effects of vortioxetine on contextual freezing might be confounded by a
potential effect on pain sensitivity. The effect of vortioxetine on pain
perception as measured by the hotplate test is shown in Fig. 4.
Vortioxetine signiﬁcantly reduced nociception, assessed as increased
paw withdrawal latency as compared to vehicle injected subjects by
one-way ANOVA [F(3, 28)=3.0, Pb0.05]. Post hoc tests showed a signif-
icant increase in paw withdrawal latency for vortioxetine at 10 mg/kg
versus vehicle-treated subjects (Pb0.01), while no signiﬁcant effect
was seen at 2.5 or 5 mg/kg.
Fig. 4. Effect of vortioxetine on pain perception measured by hotplate test. The latency
to the ﬁrst sign of withdrawal behavior (time of aversive withdrawal) was determined.
Data were analyzed using one-way ANOVA followed by Dunnett's post hoc test com-
paring all treatments, and are shown as mean time (s)±SEM with the number (n) of
animals per group. **Pb0.01.
46 A. Mørk et al. / Pharmacology, Biochemistry and Behavior 105 (2013) 41–503.4. Microdialysis
The effects of vehicle and vortioxetine on extracellular levels of ACh
andHA in themedial prefrontal cortexwere expressed as the percentage
of their baseline concentrations in the dialysates and are shown in Fig. 5.Fig. 5. Vortioxetine increased acetylcholine and histamine levels in the medial prefrontal
cortex of freely-moving rats. Rats were anesthetized and intracerebral guide cannulas/
microdialysis probeswere implanted, followed by a two-day recovery period. For each an-
imal, the average of the 3–4 consecutive samples collected immediately preceding com-
pound administration was used as the basal level and was set to 100%. The percentage
in relation to baseline values for acetylcholine (a) and histamine (b) were calculated for
each time point. Data are expressed as mean±SEM. Statistical analysis was performed
using two-way repeated measures ANOVA with Bonferroni post-hoc test comparing all
groups versus vehicle control. * or # Pb0.05; ** or ##Pb0.01.For ACh, two-way repeated measures ANOVA indicated signiﬁcant ef-
fects by vortioxetine treatment [F(3, 288)=5.5, Pb0.05], and by time
[F(11, 288)=8.0, Pb0.001], but no treatment×time interaction was
found [F(33, 288)=0.7, NS] (Fig. 5a). ACh levels of the vehicle group at
20, 40, 60 and 80 minwere 146%, 103%, 83%, and75% of baseline, respec-
tively, with the early peak likely due to the fact that ACh in the prefrontal
cortex is sensitive to injection stress. Post hoc (Student–Newman–Keuls)
analyses indicated that vortioxetine at 5 and 10 mg/kg increased the
levels of ACh to 224% and 204% of baseline 20 min after injection,
which differed signiﬁcantly from the vehicle group (Pb0.05). An enhanc-
ing effect of vortioxetine was also seen at all three doses (2.5, 5 and
10 mg/kg) 60 min after administration, with respective ACh levels of
184%, 151%, and 143% of baseline (Pb0.05 for all doses).
ForHA, two-way repeatedmeasuresANOVAalso showeda signiﬁcant
effect by vortioxetine treatment [F(3, 199)=32.3, Pb0.001] (Fig. 5b). In
addition, there was a signiﬁcant effect by time [F(12, 199)=19.7,
Pb0.001], as well as a signiﬁcant treatment×time interaction [F(36,
199)=3.0, Pb0.001]. Post hoc tests indicated that the group treated
with 2.5 mg/kg vortioxetine showed signiﬁcantly higher HA levels
in the medial prefrontal cortex relative to baseline (325%) compared
to vehicle (152%) at 40 min (Pb0.01). More pronounced effects of
vortioxetine were seen at 10 mg/kg, since HA levels were signiﬁcantly
higher than those in the vehicle control group at more time points: 40,
60, 80, 100 and 120 min (Pb0.01 for all indicated time points) (Fig. 5b).
At 5 mg/kg, vortioxetine did not produce a signiﬁcant effect on HA levels
compared to vehicle-treated animals. However, it was observed that an-
imals in this group had higher absolute baseline HA levels compared to
other groups (respective HA levels: 82±5, 57±9, 107±23, 65±
18 fmol/sample, for vehicle, 2.5 mg/kg, 5 mg/kg and 10 mg/kg). Further-
more, a one-way repeated measures ANOVA on pre-injection and
post-injection levels of HA demonstrated that vortioxetine at 5 mg/kg
signiﬁcantly increased the HA levels [F(9, 36)=8.0, Pb0.0001].
4. Discussion
The results of the present study demonstrated that vortioxetine
improves contextual fear memory in rats when administered before
or immediately after acquisition. Vortioxetine increased the condi-
tioned freezing time without altering baseline freezing behavior and
without increasing pain sensitivity of the animals. Vortioxetine also
increased episodic memory in the rat. The present work also indicates
that the effects of vortioxetine on memory function may partly in-
volve increases in extracellular ACh and HA levels in the medial pre-
frontal cortex.
Clinical doses of vortioxetine (5–20 mg daily) achieve 50–90%
5-HTT occupancies (Areberg et al., 2012). As summarized in Table 1,
when administered in the rat at 1–10 mg/kg doses, vortioxetine
would also generate this range of 5-HTT occupancies, as well as
meaningful occupancies at the 5-HT3, 5-HT7, 5-HT1B, and 5-HT1A re-
ceptors as further discussed below.
Vortioxetine increased contextual freezing when administered be-
fore acquisition, indicating enhanced fear-conditionedmemory. It is in-
teresting that vortioxetine also enhanced memory consolidation, since
vortioxetine augmented contextual freezingwhen administered imme-
diately after acquisition. Vortioxetine enhanced conditioned-fearmem-
orywhen administered before acquisition at the 10 mg/kg dose, while a
trend towards increase was observed at 5 mg/kg. With regard to
memory consolidation, an enhancement was seen for vortioxetine at
the 5 mg/kg dose only. It is not unusual that the dose–response effects
for acquisition and consolidation are different (Colon-Cesario et al.,
2006; Hubbard et al., 2007; Montezinho et al., 2010). As discussed in
the previous report (Montezinho et al., 2010), exposure to novel envi-
ronments induced increases in hippocampal extracellular 5-HT levels
(Kobayashi et al., 2008). Moreover, an electric foot-shock signiﬁcantly
enhanced extracellular efﬂux of 5-HT in the rat hippocampus, as mea-
sured by in vivo microdialysis (Hajos-Korcsok et al., 2003). Thus,
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tions, explaining that different doses are required to obtain signiﬁcant
changes in fear conditioning.
Several lines of evidence indicate that the effects of vortioxetine in
the contextual freezing test are due to improved memory rather than
non-speciﬁc effects on anxiety-like states or pain sensitivity. First,
only the highest dose of vortioxetine had an effect in the hotplate test
of nociception; thus drug-induced increases in shock sensitivity would
not adequately explain the mnemonic effects of vortioxetine at doses
lower than 10 mg/kg (Fig. 2b). Second, the effect of vortioxetine on
pain sensitivity should not confound any positive mnemonic effects in
the fear conditioning experiments. Previously we have used hotplate
test to rule out the inﬂuence of pain sensitivity on the acquisition of
the association between the conditioning fear stimulus and the context
(Montezinho et al., 2010). An increase in pain sensitivity might con-
found fear conditioning results, although focused studies suggest that
different fear responses do not seem to be directly determined by pain
perception (Lehner et al., 2010). An analgesic effect of vortioxetine
(10 mg/kg) would mean a reduction in shock sensitivity or lowering
the aversive hedonic value of the shock in the fear conditioning exper-
iments, and thus would only serve to reduce conditioned fear perfor-
mance rather than enhance it. Furthermore, the positive effects of
vortioxetine on acquisition and consolidation of contextual fear memo-
ry are unlikely to be due an anxiogenic cause. In fact, vortioxetine does
have an anxiolytic effect in the social interaction and conditioned
fear-induced ultrasonic vocalization tests (Mørk et al., 2012). In addi-
tion, vortioxetine did not seem to be able to increase the expression of
contextual fear when it was administered 60 min before the retention
test as shown in Fig. 2c. Finally, vortioxetine also showed an effect in
the novel object recognition test, which does not utilize aversive or
anxiogenic stimuli.
The neuro-circuitries of both contextual fear conditioning and novel
object recognition in relation to learning and memory involve the pre-
frontal cortex and other brain regions including the amygdala and hip-
pocampus (Bird and Burgess, 2008; Aggleton et al., 2011; Antunes and
Biala, 2012). The enhancedmemory elicited by vortioxetinemay beme-
diated by modulations in neurotransmitters levels in these brain re-
gions as a consequence of its action at the various serotonergic
targets. At the neurochemical level, the extracellular outputs of 5-HT,
dopamine and norepinephrine in the medial prefrontal cortex and the
ventral hippocampuswere increased by vortioxetine, as reported previ-
ously (Bang-Andersen et al., 2011;Mørk et al., 2012). The importance of
5-HT in the brain, especially the prefrontal cortex, with regard to cogni-
tion has been demonstrated in 5-HT depletion and augmentation stud-
ies in animals (Clarke et al., 2004, 2007; Khaliq et al., 2006). In
otherwise healthy human subjects, depletion of the 5-HT precursor,
tryptophan, also negatively impacts cognitive function (Riedel et al.,
2002; Sambeth et al., 2007; Mendelsohn et al., 2009).
In the present study, vortioxetine also increased extracellular ACh
and HA levels in the medial prefrontal cortex. ACh plays a central role
in memory and learning, and the memory-enhancing effects of ACh ele-
vations have been consistently demonstrated with acetylcholinesterase
inhibitors such as donepezil and physostigmine (Degroot and Parent,
2000; Pepeu and Giovannini, 2009; Savage, 2012). It has been demon-
strated that stimulation of 5-HT1A receptors, located postsynaptically,
increases hippocampal and cortical efﬂux of ACh in the rat (Izumi et al.,
1994; Consolo et al., 1996). Moreover, 5-HT3 receptors, located on
GABAergic interneurons in the forebrain, maintain an inhibitory basal
tone on the release of ACh and norepinephrine (Matsumoto et al.,
1995; Yan, 2002). Thus, a reduced inhibitory tone via blockade of
5-HT3 receptors may contribute to the increased extracellular levels
of neurotransmitters seen in the present and previous studies
(Bang-Andersen et al., 2011; Mørk et al., 2012). Central HA is important
for attention and vigilance, as well as for short-term memory and
long-term memory (Kay, 2000; Brioni et al., 2011; Kohler et al., 2011;
Miwa et al., 2011). Accordingly, performance in the novel objectrecognition test was impaired in H1 receptor knockout and H2 receptor
knockout mice compared to their respective wild-type mice (Dai et al.,
2007), and both spatial and episodic memory were impaired in HA de-
carboxylase knockout mice (Dere et al., 2003; Acevedo et al., 2006). Var-
ious histamine H3 receptor antagonists, which increase extracellular
levels ofmany neurotransmitters, including HA, improved cognitive per-
formance assessed in multiple animal behavioral models (Hancock,
2006;Wijtmans et al., 2007; Bonaventure et al., 2007; Brioni et al., 2011).
The activities of vortioxetine on 5-HT receptors and on 5-HTT have
been shown to increases extracellular 5-HT levels to meaningful levels
for antidepressant activity in the clinic (Mørk et al., 2012; Areberg et
al., 2012). The activities of vortioxetine at the 5-HT3, 5-HT7, 5-HT1A
and 5-HT1B receptors as potential mechanisms mediating the
memory-enhancing effects are discussed below.
Overall, the serotonergic system plays a signiﬁcant role in learning
and memory, in particular by interacting with the cholinergic,
glutamatergic, dopaminergic or GABAergic systems (Buhot et al., 2000;
Meneses, 2004; Ogren et al., 2008). Interestingly, benzimidazole–
arylpiperazine derivatives with mixed 5-HT1A receptor partial agonism
and 5-HT3 receptor antagonism have been shown to exert effects in a
passive avoidance learning test (Lopez-Rodriguez et al., 2004). This
supports the memory enhancing effects of vortioxetine in the acquisi-
tion and consolidation of contextual fear conditioning and novel object
recognition tests. Vortioxetine is a potent 5-HT3 receptor antagonist
(Ki=3.7 nM). Blockade of 5-HT3 receptors may contribute to cognition
directly and indirectly as the result of downstream effects on the cholin-
ergic system. Previous data have suggested the beneﬁcial effects of
5-HT3 receptor antagonists on cognition and memory, though such
compounds have not yet reached clinical practice in this respect
(Brambilla et al., 1993; Fontana et al., 1995; Pitsikas and Borsini, 1996;
Roychoudhury and Kulkarni, 1997; Arnsten et al., 1997). Preclinical evi-
dence of cognition- and memory-enhancing effects by 5-HT3 receptor
antagonism includes itasetron in a multiple choice avoidance behav-
ioral task (Pitsikas and Borsini, 1996). In scopolamine-treated mice,
ondansetron attenuated the performance deﬁcits (Roychoudhury and
Kulkarni, 1997), suggesting the role of 5-HT3 receptors in the normaliza-
tion of the cholinergic system disrupted by scopolamine. Furthermore,
blockade of 5-HT3 receptors may also enhance glutamate transmission
since these receptors can suppress both the spontaneous ﬁring and
N-methyl-D-aspartic acid-evoked responses of the pyramidal neurons
in the rat medial prefrontal cortex (Ashby et al., 1991; Liang et al.,
1998). As previously mentioned, the 5-HT3 receptor seems to exert an
inhibitory tone on the ACh efﬂux in the brain. In the present study, the
effect of vortioxetine on the extracellular levels of ACh did not increase
further by raising the dose from 2.5 to 10 mg/kg. If the 5-HT3 receptor
is involved in this effect the maximal effect at 2.5 mg/kg may be
explained by the fact that vortioxetine occupies the 5-HT3 receptor by
100% after administration of only 1 mg/kg (Table 1).
Vortioxetine is a 5-HT7 receptor antagonist (Ki=19 nM). Memory
enhancing effects of 5-HT7 antagonists have been shown in preclinical
models (Meneses, 2004; McLean et al., 2009; Horiguchi et al., 2011;
Horisawa et al., 2011). In a Pavlovian/instrumental autoshaping learn-
ing task, the 5-HT7 receptor antagonists SB-269970 and DR 4004 re-
versed scopolamine- or dizocilpine-induced amnesia (Meneses, 2004).
The 5-HT7 receptor antagonist SB-269970 also signiﬁcantly attenuated
sub-chronic phencyclidine (PCP)-induced reversal learning deﬁcits in
female rats (McLean et al., 2009), and similarly, SB-269970 dose-
dependently reversed PCP-induced deﬁcits in a novel object recognition
test (Horiguchi et al., 2011). An enhancement of glutamate transmis-
sion may play a role in the effects of 5-HT7 receptor antagonism, since
5-HT7 receptor activation can decrease the glutamate release of
glutamatergic cortico-raphe neurons directly or via GABAergic neurons
in the dorsal raphe (Harsing, 2006; Duncan and Congleton, 2010).
Another recent report showed that SB-269970 improved recognition
memory with a 24 h delay in the novel object recognition test as used
in the present study (Waters et al., 2012), further supporting the
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for the memory-enhancing effect of vortioxetine. Interestingly,
SB-269970 at an inactive dose augmented the cognition-enhancing efﬁ-
cacy of escitalopram in a rat prefrontal cortex-dependent attentional
set-shifting task (Nikiforuk, 2012), indicating a synergistic effect be-
tween 5-HT7 antagonism and 5-HTT inhibition, both of which are part
of the target proﬁle of vortioxetine. It should be noted that vortioxetine
has a 10-fold lower in vitro afﬁnity for rat 5-HT7 (Ki=200 nM) com-
pared with human 5-HT7 receptors (Ki=19 nM) (Mørk et al., 2012).
Thus, the contribution of the 5-HT7 receptor in the clinic may be
underestimated when predicted from preclinical models.
The inhibitory 5-HT1A receptor serves as both a somatodendritic
autoreceptor and a postsynaptic heteroreceptor with important func-
tions in learning and memory in brain regions such as the dorsal raphe,
entorhinal cortex, hippocampus, and central amygdala (Chalmers and
Watson, 1991; Polter and Li, 2010). Agonists of the 5-HT1A receptor
have a memory enhancing proﬁle (Meneses and Hong, 1999; Meeter et
al., 2006; Newman-Tancredi et al., 2009; Depoortere et al., 2010). For ex-
ample, the activation of 5-HT1A receptors by 8-OH-DPAT can reverse the
learning deﬁcit induced by scopolamine and dizocilpine in an
autoshaping learning task (Meneses andHong, 1999). Furthermore, sim-
ilar to the afﬁnity of vortioxetine for 5-HT7 receptors, its in vitro afﬁnity
at the 5-HT1A receptors (Ki=230 nM) is ~15-fold lower than at human
5-HT1A receptors (Ki=15 nM) (Bang-Andersen et al., 2011), raising the
possibility that activity at 5-HT1A receptorsmay contribute to the clinical
activity of vortioxetine to a higher degree thanwhat is apparent froman-
imal studies. However, after administration of the highest dose tested in
this study (10 mg/kg) vortioxetine occupies the 5-HT1A receptor by ap-
proximately 35% (Table 1). Thus, a 5-HT1A receptor contribution of
vortioxetine can be expected in preclinical studies at high doses.
Brain 5-HT1B receptors function as inhibitory autoreceptors on se-
rotonergic neurons and as heteroreceptors on neurons of other neu-
rotransmitters such as ACh and glutamate (Pazos and Palacios,
1985; Olivier and Oorschot, 2005). In the dorsal subiculum, 5-HT1B re-
ceptors are located on CA1 pyramidal axon terminals as inhibitory
heteroreceptors (Ait et al., 1995), and activation of these receptors at-
tenuates glutamate transmission in the hippocampus (Boeijinga and
Boddeke, 1996; Mlinar et al., 2003). Administration of a selective
5-HT1B receptor antagonist NAS-181 caused a dose-dependent increase
in ACh levels in the frontal cortex and ventral hippocampus of freely
moving rats (Hu et al., 2007). There is evidence that the 5-HT1B receptor
is involved in learning and memory (Meneses, 2001, 2007; Eriksson
et al., 2008). For example, in an associative autoshaping learning task,
a 5-HT1B receptor inverse agonist (SB-224289) facilitated learning
consolidation and was able to reverse the cognitive deﬁcits induced
by either the cholinergic inhibitor scopolamine or the glutamatergic an-
tagonist dizocilpine (Meneses, 2001). In an aversive contextual learning
task in mice, NAS-181 dose-dependently improved passive avoidance
retention performance (Eriksson et al., 2008). Thus, the partial agonist
activity of vortioxetine at the 5-HT1B receptor (Ki=33 nM) may also
play a role in its memory-enhancing properties.
5. Conclusions
The present study demonstrated that vortioxetine enhances con-
textual and episodic memory in rat behavioral models and increases
extracellular ACh and HA levels in the rat medial prefrontal cortex.
The multimodal effect of vortioxetine through various 5-HT targets,
may contribute to improving cognitive dysfunction in MDD as ob-
served in a recent clinical study (Katona et al., 2012).
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